Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?
Clinical medicine. Oncology · 2009
DOI: 10.4137/cmo.s1012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical medicine. Oncology, 2009. Verfasst von Wolfgang Otto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Regensburg, Germany. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Photodynamic diagnosis (PDD) of superficial bladder cancer decreases recurrence rates. We present oncological results of a randomized, prospective study, comparing transurethral resection (TUR) performed under conventional white light (WL) with PDD. The follow-up period is the longest reported to date. As costs might be reimbursed by prolonged recurrence-free survival in certain patients cost analysis in regard to risk-groups was performed. Material and methods Using chi-square test and log-rank test we compared recurrence rates of 103 patients after WL-TUR and of 88 patients after PDD-TUR. Cost analysis was performed according to risk-groups of recurrence.
Results
Mean follow-up was 99 months. Recurrence rate was 57% in WL vs. 28% in PDD (p < 0.001). Costs incurred by subsequent TUR averaged € 2310 per WL patient vs. € 713 per PDD patient. Savings per patient by PDD amounted to € 1597. PDD costs were reimbursed in low, intermediate and high risk patients, respectively.
Conclusions
PDD-TUR is significantly superior to conventional WL-TUR in terms of recurrence rate. While economic benefit is most prominent in intermediate risk patients, PDD related costs are reimbursed in all risk-groups.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, University of Regensburg, Germany.
Zitieren
APA
Otto, W., Burger, M., Fritsche, H. M., Blana, A., Roessler, W., Knuechel, R., Wieland, W. F., & Denzinger, S. (2009). Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?. Clinical medicine. Oncology. https://doi.org/10.4137/cmo.s1012
Vancouver
Otto W, Burger M, Fritsche HM, Blana A, Roessler W, Knuechel R, et al. Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?. Clinical medicine. Oncology. 2009. doi:10.4137/cmo.s1012
BibTeX
@article{Otto2009,
author = {Otto, Wolfgang and Burger, Maximilian and Fritsche, Hans-Martin and Blana, Andreas and Roessler, Wolfgang and Knuechel, Ruth and Wieland, Wolf F and Denzinger, Stefan},
title = {Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?},
journal = {Clinical medicine. Oncology},
year = {2009},
doi = {10.4137/cmo.s1012}
}
EUVIMED